CSPC Pharmaceutical Group (HKSE:01093) Accounts Payable & Accrued Expense : HK$9,940 Mil (As of Dec. 2023)

View and export this data going back to 1994. Start your Free Trial

What is CSPC Pharmaceutical Group Accounts Payable & Accrued Expense?

CSPC Pharmaceutical Group's quarterly accounts payable & accrued expense declined from Jun. 2023 (HK$9,389 Mil) to Sep. 2023 (HK$0 Mil) but then increased from Sep. 2023 (HK$0 Mil) to Dec. 2023 (HK$9,940 Mil).

CSPC Pharmaceutical Group's annual accounts payable & accrued expense increased from Dec. 2021 (HK$8,010 Mil) to Dec. 2022 (HK$8,623 Mil) and increased from Dec. 2022 (HK$8,623 Mil) to Dec. 2023 (HK$9,940 Mil).

CSPC Pharmaceutical Group Accounts Payable & Accrued Expense Historical Data

The historical data trend for CSPC Pharmaceutical Group's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSPC Pharmaceutical Group Accounts Payable & Accrued Expense Chart

CSPC Pharmaceutical Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

6,042.99

6,321.72

8,010.30

8,623.21

9,940.07

CSPC Pharmaceutical Group Quarterly Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															8,623.21	-	9,388.67	-	9,940.07

CSPC Pharmaceutical Group Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

CSPC Pharmaceutical Group (HKSE:01093) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CSPC Pharmaceutical Group Ltd (HKSE:01093) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

CSPCY:USA CHJTF:USA CVG:Germany

Address

No. 226 Huanghe Street, Hebei Province, Shijiazhuang, CHN, 050035

Website

https://www.cspc.com.hk

CSPC Pharmaceutical Group listed on the Hong Kong Stock Exchange in 1994 and is one of the largest pharmaceutical companies in China. Its biggest business segment is the finished drugs segment which accounts for nearly 80% of its total revenue. Now it has a diversified pipeline portfolio in seven therapeutic areas including nervous system diseases, oncology, anti-infective to cardiovascular disease, respiratory system disease, and metabolism. CSPC also has a bulk drug product segment including vitamin C, antibiotics, and a caffeine series.

CSPC Pharmaceutical Group (HKSE:01093) Headlines

No Headlines